Anika Therapeutics (STU:AKP) Short Interest


STU:AKP Anika Therapeutics Inc STU:AKP
66 GF Score
Price €13.10
GF Value €17.79
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:AKP vs LFCR, DERM, ASRT: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anika Therapeutics Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Short Interest falls into.


STU:AKP
66GF Score
Anika Therapeutics Inc STU:AKP
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.10 is trading 26.4% below its estimated GF Value™ of €17.79. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • Short Interest:
  • GF Value™: €17.79 vs. price of €13.10 (26.4% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score

Get the complete analysis for STU:AKP

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.10
Price
€17.79
GF Value